scispace - formally typeset
M

Michal Starnawski

Researcher at Hoffmann-La Roche

Publications -  8
Citations -  1002

Michal Starnawski is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Basal cell carcinoma & Vismodegib. The author has an hindex of 4, co-authored 8 publications receiving 904 citations.

Papers
More filters
Journal ArticleDOI

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Atsushi Ohtsu, +11 more
- 20 Oct 2011 - 
TL;DR: The Avastin in Gastric Cancer (AVAGAST) trial as discussed by the authors evaluated the efficacy of adding bevacizumab to capecitabine-cisplatin in the first-line treatment of advanced gastric cancer.

Bevacizumab in Combination With Chemotherapy As First-LineTherapyinAdvancedGastricCancer:ARandomized, Double-Blind, Placebo-Controlled Phase III Study

Atsushi Ohtsu, +11 more
TL;DR: Although AVAGAST did not reach its primary objective, adding bevacizumab to chemotherapy was associated with significant increases in progression-free survival and overall response rate in the first-line treatment of advanced gastric cancer.
Journal ArticleDOI

Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients.

Jean-Jacques Grob, +10 more
- 20 May 2013 - 
TL;DR: Aberrant Hedgehog signaling is the key driver in BCC pathogenesis and Vismodegib, a first-in-class Hh signaling booster, is a new drug candidate for BCC.
Journal ArticleDOI

MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas.

Rainer Kunstfeld, +7 more
- 20 May 2014 - 
TL;DR: The MIKIE study assesses the efficacy and safety of 2 intermittent vismodegib dosing regimens in pts with multiple BCCs and stratified by BCCNS status, geographic region, and immunosuppression status.
Journal ArticleDOI

Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma

John T. Lear, +10 more